

# HIV PREVENTION PIPELINE: PRODUCTS TO WATCH

PRECLINICAL	PHASE I	PHASE II	PHASE III	IMPLEMENTATION
<p><b>Hundreds of...</b></p> <ul style="list-style-type: none"> <li> <b>ARV-Based</b></li> <li> <b>MPTs</b></li> <li> <b>Vaccine candidates</b></li> <li> <b>bNAbs candidates</b></li> </ul>	<ul style="list-style-type: none"> <li> <b>3-Monthly DPV + LNG</b></li> <li> <b>On-Demand TAF + EVG</b></li> <li> <b>Vaccine candidates</b></li> <li> <b>Combo bNAb candidates</b></li> </ul>	<ul style="list-style-type: none"> <li> <b>Event-Driven FTC/TAF</b></li> <li> <b>On-Demand TFV</b></li> <li> <b>Combo bNAb candidates</b></li> </ul>	<ul style="list-style-type: none"> <li> <b>Monthly MK-8527</b></li> </ul>	<ul style="list-style-type: none"> <li> <b>Daily TDF/FTC</b></li> <li> <b>Daily FTC/TAF</b></li> <li> <b>2-Monthly CAB</b></li> <li> <b>6-Monthly LEN</b></li> <li> <b>Monthly DPV</b></li> </ul>
<p>The US Govt's shut down of USAID ended six critical HIV research projects. With MATRIX, the field lost an important effort to develop diverse, on-demand, and multi-purpose products, especially for young women. The ADVANCE and BRILLIANT projects were researching a range of vaccine candidates while also building African-led research agendas.</p> <ul style="list-style-type: none"> <li> <b>Long-acting implants</b></li> <li> <b>Multi-purpose vaginal ring</b></li> <li> <b>Vaginal &amp; mucosal inserts</b></li> <li> <b>Vaginal film</b></li> <li> <b>Vaccines</b></li> </ul>		<p><b>BIO-EQUIVALENCE</b></p>		
		<ul style="list-style-type: none"> <li> <b>4-Monthly CAB</b></li> <li> <b>3-Monthly DPV</b></li> <li> <b>Weekly LEN *</b></li> </ul>	<ul style="list-style-type: none"> <li> <b>12-Monthly LEN</b></li> <li> <b>Daily DPP</b></li> </ul>	

**KEY:** ARV-based MPTs Vaccines bNAbs

bNAb: broadly-neutralizing antibodies, CAB: Cabotegravir, DPP: dual prevention pill, DPV: Dapivirine, EVG: Elvitegravir, F/TAF: emtricitabine/tenofovir alafenamide, LEN: Lenacapavir, LNG: Levonorgestrel, TAF: tenofovir alafenamide, TDF/FTC: tenofovir disoproxil fumarate-emtricitabine

\* Weekly LEN has been submitted and is pending regulatory approval